Management of Side Effects of Everolimus Treatment for Metastatic Renal Cell Carcinoma

HANDLE Web Site Open Access
  • Mikami, Kazuya
    The Department of Urology, Kyoto Prefectural University of Medicine Graduate School of Medical Science
  • Hongo, Fumiya
    The Department of Urology, Kyoto Prefectural University of Medicine Graduate School of Medical Science
  • Miki, Tsuneharu
    The Department of Urology, Kyoto Prefectural University of Medicine Graduate School of Medical Science

Bibliographic Information

Other Title
  • 分子標的治療の副作用対策: Everolimus
  • ブンシ ヒョウテキ チリョウ ノ フクサヨウ タイサク : Everolimus

Search this article

Abstract

Treatment with everolimus is known to prolong progression-free survival in patients with renal cell carcinoma resistant against tyrosine-kinase inhibitor therapy. The side effects must be known for more effective use of this drug. Information of side effects was collected from a randomized controlled study, the early post-marketing phase vigilance and from our own experience. Interstitial lung disease (ILD) was a potentially severe side effect. Incidence of ILD was relatively large compared with that of other target therapy agents. Infections, thrombocytopenia, stomatitis and others were experienced as other side effects. However, there were few uncontrollable side effects. Management of side effects of everolimus can be improved by obtaining sufficient knowledge.

Journal

  • Hinyokika Kiyo

    Hinyokika Kiyo 58 (11), 647-650, 2012-11

    泌尿器科紀要刊行会

Keywords

Details 詳細情報について

Report a problem

Back to top